Replies to post #73118 on Avid Bioservices Inc (CDMO)

[jessme]

Speaking of TNT China. I wonder if CTL is getting any of this money and if so where is our cut? Don't we supposedly get 50% of CTL's cut.

Shanghai MediPharm Biotech

Shanghai MediPharm Biotech is a wholly-owned subsidiary of Medipharm Biotech Biopharmaceutical Ltd (Bermuda) focused on becoming China’s leading oncology biopharma by providing novel, antibody-based, targeted radio immunotherapy for malig-nant cancers.

Following 15 years of R&D in antibody related biopharmaceuticals, the company has a strong intellectual property portfolio, including Vivatuxin®, a chimeric tumor necrosis therapy approved by China’s State Food and Drug Administration for lung cancer and launched in 2007, as well as other candidates in radio immunotherapy. Through a strategic marketing collaboration study with the Ministry of Health of China currently covering 101 hospitals, the company has agreements to supply 20,000 doses of Vivatuxin®, priced at $3,000 each, used for the treatment of advanced lung cancer patients, who have previously failed at least one course of chemotherapy, and is negotiating collaboration with additional 50 hospitals.
Vivatuxin® is undergoing Phase III clinical study registrations for glioma and liver cancer, as well as preclinical trials for colorectal and breast cancers. Finally, the company has two exclusive licenses in radio immunotherapy technology platforms from University of Southern California Cancer Therapeutic Lab, namely Lym-1 for non-Hodgkin lymphoma, which started Phase I clinical trials in 2010, and TNT fusion protein technology for solid tumors.
Currently, MediPharm has a staff of 53 professionals, and with
105,000 square feet GMP-approved world class manufacturing
facilities, which include a 500L B. Braun bioreactor, the company
has the capacity to produce 100,000 drug doses per year.

Vivatuxin® is expected to generate $45.1 million revenue and $13.8 million net profit in 2011,

$92.8 million revenue and $36.1 million net profit in 2012,

and $143.3 million revenue and $52.1 million net
profit in 2013.

http://www.wallstreetresearch.org/

[Threes]

Thanks jessme for the actual #'s China TNT.

I would not hold my breath on us getting any of those dollars.